Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an analyst and investor event focused on lacutamab, an asset with path to potential Accelerated Approval based on existing long-term follow-up data of the Phase 2 TELLOMAK study, providing both clinical perspectives and market outlook. The event will be held in person and virtually on Tuesday, October 28, 2025, from 8:00 a.m. to 10:00 a.m. ET / 1:00 p.m. to 3:00 p.m. CET, at the Park Terrace Hotel on Bryant Park in New York.

The program will feature Pierluigi Porcu, M.D., Division Chief for Hematology and BMT at University of Kentucky, Lexington, a world expert in T-cell lymphomas, who will provide medical perspectives on results from the Phase 2 TELLOMAK trial, which evaluated lacutamab in patients with relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL). ZS Associates, leading experts in life sciences and healthcare markets, will describe the eligible U.S. cutaneous T-cell lymphoma patient population based on real-world claims data. Finally, Innate Pharma’s management will provide updates on the planned Phase 3 trial, regulatory pathway in CTCL, including path to potential accelerated approval in Sézary syndrome, and commercial opportunity for lacutamab.

“We look forward to engaging with the investor community in New York to share the latest updates and perspectives on lacutamab, a product which has the potential to meaningfully improve outcomes and quality of life for CTCL patients with high unmet medical needs while creating significant value for shareholders,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. Supported by strong TELLOMAK Phase 2 results, lacutamab is positioned for accelerated approval in Sézary syndrome once the confirmatory study in CTCL is underway. New real-world data showing a larger eligible CTCL population in the U.S. than previously reflected in public data further reinforce our commitment to advancing lacutamab for patients, with the confirmatory Phase 3 protocol nearing completion.”

The event will feature live Q&A opportunities.

To register for in person participation or virtual access, click here.

A replay will be available in the investors section of Innate Pharma website after the event.